Eranz
Brand names,
Eranz
Analogs
Eranz
Brand Names Mixture
Eranz
Chemical_Formula
C24H29NO3
Eranz
RX_link
http://www.rxlist.com/cgi/generic/donepezil.htm
Eranz
fda sheet
Eranz
msds (material safety sheet)
Eranz
Synthesis Reference
No information avaliable
Eranz
Molecular Weight
379.492 g/mol
Eranz
Melting Point
206.72 oC
Eranz
H2O Solubility
2.931 mg/L
Eranz
State
Solid
Eranz
LogP
4.09
Eranz
Dosage Forms
Tablet; Tablet (orally disintegrating)
Eranz
Indication
For management of symptoms associated with Alzheimer's Disease
Eranz
Pharmacology
Donepezil is a centrally acting reversible acetyl cholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine. It is well absorbed in the gut with an oral bioavailability of 100% and easily crosses the blood-brain barrier. Because it has a half life of about 70 hours, it can be taken once a day. Initial dose is 5 mg per day, which can be increased to 10 mg per day after an adjustment period of at least 4 weeks. Donepezil is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. Donepezil is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, donepezil's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. There is no evidence that donepezil alters the course of the underlying dementing process.
Eranz
Absorption
Donepezil is well absorbed with a relative oral bioavailability of 100% and reaches peak plasma concentrations in 3 to 4 hours.
Eranz
side effects and Toxicity
Symptoms of overdose include severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, collapse and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved.
Eranz
Patient Information
Patient Info
ARICEPT� (donepezil HCl) is indicated for the treatment of symptoms of mild to moderate Alzheimer�s disease.
ARICEPT� (donepezil HCl) is well tolerated but may not be for everyone. Some people may experience nausea, diarrhea, insomnia, vomiting, muscle cramps, fatigue or loss of appetite. In studies, these side effects were usually mild and temporary. Some people taking ARICEPT� (donepezil HCl) may experience fainting. People at risk for ulcers should tell their doctors because their condition may get worse.
Eranz
Organisms Affected
Humans and other mammals